Current perspectives of SA-4-1BBL in immune modulation during cancer (Review)

Zhou,Shu-Ni; Ran,Rui-Zhi; Tan,Li-Li; Guo,Hao

doi:10.3892/etm.2018.5729

Current perspectives of SA-4-1BBL in immune modulation during cancer (Review)

Authors:
- Shu-Ni Zhou
- Rui-Zhi Ran
- Li-Li Tan
- Hao Guo
View Affiliations

Affiliations: Department of Cardiology, The Ethnic Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China, Department of Medical Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, Hubei 445000, P.R. China
Published online on: January 9, 2018 https://doi.org/10.3892/etm.2018.5729
Pages: 2699-2702
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A recombinant co-stimulatory molecule capable of inducing multiple effects on varied immune cells when present in its soluble active form is termed as SA-4-1BBL. It has been reported to influence innate, adaptive, and regulatory immune cells. Recent studies confirmed its engagement with receptor, 4-1BB leading to collection of interleukin-2 (IL-2) that in turn overcomes Treg suppression. Further, a vast number of pre- clinical studies reported its therapeutic efficacy in the form of adjuvant subunit in cancer vaccines. Furthermore, it is also observed that it contributes significantly towards communication bridge of CD4 and NK cells. On the other hand, depletion of either NK or CD4 cells negated SA-4-1BBL's antitumor protection. The present review article is focused on the current updates of this molecule pertaining to the filed of cancer therapeutics or cancer preventives.

View Figures

View References

1	Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, et al: A multifunctional role for adjuvant anti-4-1BB therapy in augmenting antitumor response by chimeric antigen receptor T cells. Cancer Res. 77:1296–1309. 2017. View Article : Google Scholar : PubMed/NCBI
2	Tian YY, Jia CM, Li Y, Wang Y, Jiang L and Liu AC: Restoration of microRNA-373 suppresses growth of human T-cell lymphoma cells by repressing CCND1. Eur Rev Med Pharmacol Sci. 20:4435–4444. 2016.PubMed/NCBI
3	Broll K, Richter G, Pauly S, Hofstaedter F and Schwarz H: CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am J Clin Pathol. 115:543–549. 2001. View Article : Google Scholar : PubMed/NCBI
4	Fu ZX, Han JS, Liu F, Zhao ZL, Li DB, Shi L, Dong JT, Zhou Y and Cai JH: The study on specific umbilical blood Dc vaccine for Beige nude mice loaded human colorectal carcinoma to induce antitumor immunity. Eur Rev Med Pharmacol Sci. 21:2364–2371. 2017.PubMed/NCBI
5	Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, et al: 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 21:581–590. 2015. View Article : Google Scholar : PubMed/NCBI
6	Curran MA, Geiger TL, Montalvo W, Kim M, Reiner SL, Al-Shamkhani A, Sun JC and Allison JP: Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of eomesodermin. J Exp Med. 210:743–755. 2013. View Article : Google Scholar : PubMed/NCBI
7	Madireddi S, Eun SY, Lee SW, Nemčovičová I, Mehta AK, Zajonc DM, Nishi N, Niki T, Hirashima M and Croft M: Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. J Exp Med. 211:1433–1448. 2014. View Article : Google Scholar : PubMed/NCBI
8	Eun SY, Lee SW, Xu Y and Croft M: 4-1BB ligand signaling to T cells limits T cell activation. J Immunol. 194:134–141. 2015. View Article : Google Scholar : PubMed/NCBI
9	Hoffmann JM, Schmitt M, Ni M and Schmitt A: Next-generation dendritic cell-based vaccines for leukemia patients. Immunotherapy. 9:173–181. 2017. View Article : Google Scholar : PubMed/NCBI
10	Berretta M, Fisichella R, Borsatti E, Lleshi A, Ioffredo S, Meneguzzo N, Canzonieri V, Di Grazia A, Cannizzaro R, Tirelli U, et al: Feasibility of intraperitoneal trastuzumab treatment in a patient with peritoneal carcinomatosis from gastric cancer. Eur Rev Med Pharmacol Sci. 18:689–692. 2014.PubMed/NCBI
11	Lipson EJ and Drake CG: Ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 17:6958–6962. 2011. View Article : Google Scholar : PubMed/NCBI
12	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
13	Schabowsky RH, Elpek KG, Madireddi S, Sharma RK, Yolcu ES, Bandura-Morgan L, Miller R, MacLeod KJ, Mittler RS and Shirwan H: A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 28:512–522. 2009. View Article : Google Scholar : PubMed/NCBI
14	Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, Spencer T, Dillehay D, Kwon B, Chen L, et al: Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol. 178:4194–4213. 2007. View Article : Google Scholar : PubMed/NCBI
15	Sharma RK, Yolcu ES, Srivastava AK and Shirwan H: CD4⁺ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models. PLoS One. 8:e731452013. View Article : Google Scholar : PubMed/NCBI
16	Srivastava AK, Sharma RK, Yolcu ES, Ulker V, MacLeod K, Dinc G and Shirwan H: Prime-boost vaccination with SA-4-1BBL costimulatory molecule and survivin eradicates lung carcinoma in CD8⁺ T and NK cell dependent manner. PLoS One. 7:e484632012. View Article : Google Scholar : PubMed/NCBI
17	Sharma RK, Srivastava AK, Yolcu ES, MacLeod KJ, Schabowsky RH, Madireddi S and Shirwan H: SA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model. Vaccine. 28:5794–5802. 2010. View Article : Google Scholar : PubMed/NCBI
18	Melero I, Johnston JV, Shufford WW, Mittler RS and Chen L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol. 190:167–172. 1998. View Article : Google Scholar : PubMed/NCBI
19	Navabi S, Doroudchi M, Tashnizi AH and Habibagahi M: Natural killer cell functional activity after 4-1BB costimulation. Inflammation. 38:1181–1190. 2015. View Article : Google Scholar : PubMed/NCBI
20	Futagawa T, Akiba H, Kodama T, Takeda K, Hosoda Y, Yagita H and Okumura K: Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. Int Immunol. 14:275–286. 2002. View Article : Google Scholar : PubMed/NCBI
21	Sharma RK, Schabowsky RH, Srivastava AK, Elpek KG, Madireddi S, Zhao H, Zhong Z, Miller RW, Macleod KJ, Yolcu ES, et al: 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 70:3945–3954. 2010. View Article : Google Scholar : PubMed/NCBI
22	Srivastava AK, Dinc G, Sharma RK, Yolcu ES, Zhao H and Shirwan H: SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines. Cancer Res. 74:6441–6451. 2014. View Article : Google Scholar : PubMed/NCBI
23	Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH and Shirwan H: Ex vivo expansion of CD4⁺CD25⁺FoxP3⁺ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol. 179:7295–7304. 2007. View Article : Google Scholar : PubMed/NCBI
24	Madireddi S, Schabowsky RH, Srivastava AK, Sharma RK, Yolcu ES and Shirwan H: SA-4-1BBL costimulation inhibits conversion of conventional CD4⁺ T cells into CD4⁺ FoxP3⁺ T regulatory cells by production of IFN-γ. PLoS One. 7:e424592012. View Article : Google Scholar : PubMed/NCBI
25	Sharma RK, Elpek KG, Yolcu ES, Schabowsky RH, Zhao H, Bandura-Morgan L and Shirwan H: Costimulation as a platform for the development of vaccines: A peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res. 69:4319–4326. 2009. View Article : Google Scholar : PubMed/NCBI